112 filings
8-K
NMTC
NeuroOne Medical Technologies Corp
26 Mar 24
NeuroOne® Initiates Limited Commercial Launch of OneRF™ Ablation System
9:20am
8-K
NMTC
NeuroOne Medical Technologies Corp
15 Mar 24
Submission of Matters to a Vote of Security Holders
4:30pm
8-K
NMTC
NeuroOne Medical Technologies Corp
13 Feb 24
NeuroOne® Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
4:15pm
8-K
NMTC
NeuroOne Medical Technologies Corp
14 Dec 23
NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update
4:30pm
8-K
NMTC
NeuroOne Medical Technologies Corp
11 Dec 23
NeuroOne® Receives FDA 510(k) Clearance to Market its OneRF™ Ablation System
8:15am
8-K
8dhwnr yf3
16 Nov 23
NeuroOne® Announces Patent Allowance for Drug Delivery Utilizing a Novel Neural Probe
8:00am
8-K
0sjve2ak uh
14 Nov 23
Volker strengthens existing management team in areas of commercialization, business development, and reimbursement
5:28pm
8-K
wni45vy
7 Nov 23
NeuroOne® Provides Progress Update on FDA 510(k) Submission for OneRF™ Ablation System
8:15am
8-K
qtw5bg
14 Aug 23
NeuroOne® Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
4:15pm
8-K
xsv2 otmvhsxw5q62
27 Jul 23
NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock
4:02pm
8-K
xm46en2todxhkg
11 May 23
NeuroOne® Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
4:16pm
8-K
yfmesezr t1art9o43
17 Mar 23
Submission of Matters to a Vote of Security Holders
4:34pm
8-K
9aouwwpultoqpy6
10 Mar 23
Regulation FD Disclosure
5:00pm
8-K
jvjhv86egxrnbryypu8h
14 Feb 23
NeuroOne® Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
12:00am
8-K
5yp4h95
13 Jan 23
Other Events
4:15pm
8-K
cnm6kni003e1
22 Dec 22
NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2022 Financial Results
9:11am
8-K
u1sac bf02
16 Dec 22
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
4:16pm
8-K
onhr3neq8y1viyf44a0
25 Oct 22
NeuroOne® Receives FDA 510(k) Clearance to Market its Evo® sEEG System for Less than 30 Day Use
9:19am
8-K
ibf6e0erq upxq81b
14 Sep 22
Regulation FD Disclosure
8:30am
8-K
9uzdxmyzaryjq
11 Aug 22
NeuroOne® Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update
4:49pm